Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Fig. 3

Kaplan-Meier survival analyses of patients with high and low serum cytokines in the 2 cohorts. a Sorafenib-treated patients with high serum cytokine levels showed better survival with statistical (IL-5, IL-8, PDGF-BB, VEGF-A) or borderline significance (CXCL9 and TGF-α). b Patients who received hepatic arterial infusion chemotherapy showed similar survival rates regardless of serum cytokine levels

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us